Toxic Risk of Combined Radiation and Erlotinib for Lung Cancer
Author Information
Author(s): Hsieh Chen-Hsi, Chang Hou-Tai, Lin Shih-Chiang, Chen Yu-Jen, Wang Li-Ying, Hsieh Yen-Ping, Chen Chien-An, Chong Ngot-Swan, Lin Shoei Long, Chen Chun-Yi, Shueng Pei-Wei
Primary Institution: Far Eastern Memorial Hospital, Taipei, Taiwan
Hypothesis
Is the combination of stereotactic body radiotherapy and erlotinib safe and effective for treating non-small-cell lung cancer?
Conclusion
The combination of SBRT, HT, and erlotinib showed effective anti-tumor results, but potential risks of adverse effects should be monitored closely.
Supporting Evidence
- The tumor shrank significantly after treatment.
- The patient developed dyspnea and radiation pneumonitis three months post-therapy.
- Erlotinib was well tolerated as maintenance therapy.
Takeaway
Doctors combined a special type of radiation therapy with a medicine to treat a man's lung cancer, and it worked well, but it also caused some serious side effects.
Methodology
The patient received erlotinib and underwent image-guided SBRT via helical tomotherapy, delivering a total tumor dose of 54 Gy in 9 fractions.
Potential Biases
Potential bias due to the lack of a control group and reliance on a single patient's outcomes.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 77-year-old man with stage III non-small-cell lung cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website